Feature | February 28, 2014

3-D Printer Creates Transformative Device for Heart Treatment

Igor Efimov, Ph.D., and a team of researchers are developing a custom-fitted, implantable device that can deliver treatment or predict an impending heart attack before a patient shows any physical symptoms. Photo by James Byard, Washington University in St. Louis

Igor Efimov, Ph.D., and a team of researchers are developing a custom-fitted, implantable device that can deliver treatment or predict an impending heart attack before a patient shows any physical symptoms. Photo by James Byard, Washington University in St. Louis

February 28, 2014 — Igor Efimov, Ph.D., from the School of Engineering and Applied Science at Washington University in St. Louis, and an international team of biomedical engineers and materials scientists have created a 3-D elastic membrane made of a soft, flexible, silicon material that is precisely shaped to match the heart's epicardium, or the outer layer of the wall of the heart.

Current technology is two-dimensional and cannot cover the full surface of the epicardium or maintain reliable contact for continual use without sutures or adhesives. The team prints tiny sensors onto the membrane that can precisely measure temperature, mechanical strain and pH, among other markers, or deliver a pulse of electricity in cases of arrhythmia. Those sensors could assist physicians with determining the health of the heart, deliver treatment or predict an impending heart attack before a patient exhibits any physical signs.

The findings were published online in Nature Communications on Feb. 25.

"Each heart is a different shape, and current devices are one-size-fits-all and don't at all conform to the geometry of a patient's heart," says Efimov, the Lucy & Stanley Lopata Distinguished Professor of Biomedical Engineering. "With this application, we image the patient's heart through MRI [magnetic resonance imaging] or CT [computed tomography], then computationally extract the image to build a 3-D model that we can print on a 3-D printer. We then mold the shape of the membrane that will constitute the base of the device deployed on the surface of the heart."

Ultimately, the membrane could be used to treat diseases of the ventricles in the lower chambers of the heart or could be inserted inside the heart to treat a variety of disorders, including atrial fibrillation, which affects 3-5 million patients in the United States.

"Currently, medical devices to treat heart rhythm diseases are essentially based on two electrodes inserted through the veins and deployed inside the chambers," Efimov says. "Contact with the tissue is only at one or two points, and it is at a very low resolution. What we want to create is an approach that will allow you to have numerous points of contact and to correct the problem with high-definition diagnostics and high-definition therapy."

Co-leading the team with Efimov is John Rogers, Ph.D., the Swanlund chair and professor of materials science and engineering and director of the F. Seitz Materials Research Laboratory at the University of Illinois at Urbana-Champaign. Rogers, who developed the transfer printing technique, developed the sensors using semiconductor materials including silicon, gallium arsenide and gallium nitride, along with metals, metal oxides and polymers.

Recently, Google announced its scientists had developed a type of contact lens embedded with sensors that could monitor glucose levels in patients with diabetes. Efimov says the membrane his team has developed is a similar idea, though much more sophisticated. "Because this is implantable, it will allow physicians to monitor vital functions in different organs and intervene when necessary to provide therapy," he says. "In the case of heart rhythm disorders, it could be used to stimulate cardiac muscle or the brain, or in renal disorders, it would monitor ionic concentrations of calcium, potassium and sodium."

Efimov says the membrane could even hold a sensor to measure troponin, a protein expressed in heart cells and is a hallmark of a heart attack. Analysis for troponin is standard of care for patients with suspected heart attacks.

Ultimately, such devices will be combined with ventricular assist devices (VAD), Efimov says. "This is just the beginning. Previous devices have shown huge promise and have saved millions of lives. Now we can take the next step and tackle some arrhythmia issues that we don't know how to treat."

For more information: www.nature.com/ncomms/2014/140225/ncomms4329/full/ncomms4329.html

Related Content

News | Cardiac Diagnostics| September 28, 2016
Increasing stomach fat – especially the “hidden fat” in your abdomen – is associated with newly identified and...
Infinix 4D CT

Toshiba's Infinix 4D CT, which combines CT with angiography in the interventional lab.

Feature | Angiography| September 28, 2016 | Tom Watson BS, RCVT, Clinical Analyst, MD Buyline
One of the more significant advancements for interventional X-ray (IXR) in the past few years has been a significantl
European Heart Rhythm Association, EHRA White Book 2016, EP Europace supplement, cardiac rhythm device use, Europe
News | EP Lab| September 27, 2016
In August, the European Heart Rhythm Association (EHRA) and EP Europace journal announced the release of the supplement...
BioTelemetry, CE Mark, Holter analysis software
News | Holter Monitoring Systems| September 27, 2016
BioTelemetry Inc. announced in late August that the company has received CE mark approval of its Holter analysis...
ACC, American College of Cardiology, Google search, heart conditions, Health Knowledge Graphs
News | Information Technology| September 23, 2016
A Google search for heart conditions will now prominently display important questions patients should ask their doctor...
Robert M. Califf, FDA commissioner, future of cardiovascular medicine, JACC column
News | Business| September 23, 2016
Technology advances coupled with increased use of social media and personal devices could offer new possibilities for...
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
don woodlock, GE Healthcare, EP CVIS, electrophyiology
Sponsored Content | Webinar | Cardiac PACS| September 16, 2016
Cardiac rhythm management (CRM) data is becoming increasingly important in the management of patients with implantabl
EBR Systems, FDA, WiSE Technology, Wireless Stimulation Endocardially, SOLVE-CRT study

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional cardiac resynchronization therapy (CRT) in heart failure patients. Graphic courtesy of Business Wire.

News | Cardiac Resynchronization Therapy Devices (CRT)| September 15, 2016
EBR Systems Inc. announced the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption...
Overlay Init